Skip to main content

Table 2 Breast cancer risk in women stratified by site of first primary cancer diagnosed before BCa-2 in their FDRs

From: Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study

Site of first primary cancer before BCa-2 in FDR

N a

RR b

95%CI

UAT c

5

1.21

0.50

2.90

Stomach c

6

3.92

1.76

8.72

Small intestine

2

1.61

0.40

6.42

CRC

44

1.60

1.19

2.15

Liver

3

2.10

0.68

6.52

Lung c

5

1.00

0.42

2.40

Cervix c

16

1.46

0.89

2.38

Endometrium

60

2.07

1.60

2.67

Ovary

24

2.82

1.89

4.21

Female genital

2

0.79

0.20

3.17

Prostate

3

2.58

0.83

7.99

Kidney c

10

1.44

0.77

2.68

Bladder c

8

1.00

0.50

2.00

Melanoma

21

1.33

0.87

2.04

Skin

11

1.11

0.61

2.01

Nervous system

18

1.94

1.22

3.07

Thyroid

10

1.54

0.83

2.86

Endocrine gland

20

2.05

1.32

3.18

Bone

1

0.80

0.11

5.69

Connective tissue

4

1.89

0.71

5.05

NHL d

12

2.84

1.61

5.00

Hodgkin lymphoma d

3

2.06

0.67

6.40

Myeloma d

1

1.59

0.22

11.29

Leukemia d

4

0.85

0.32

2.26

CUP

5

2.24

0.93

5.38

Smoking related cancers

50

1.34

1.02

1.77

Hematological cancers

20

1.82

1.17

2.81

Any cancer other than BC

298

1.68

1.49

1.88

  1. aN, number of BC cases diagnosed during the follow-up in women
  2. bRR was estimated from Poisson regression using individuals without cancer family history as the reference. The covariates adjusted in the model included age groups (5 years), periods (5 years), parity (number of live birth: 0, 1, 2, 3, over 3), socioeconomic status (blue-collar worker, white-collar worker, farmer, private business, professional, or other/unspecified) and place of residence (big cities, northern Sweden, southern Sweden and unspecific). Significant RRs are in bold
  3. cCancers that were included as smoking-related cancers
  4. dCancers that were included as hematological cancers
  5. BC breast cancer, BCa-2 breast cancer as a second primary malignancy, FDR first-degree relative, UAT upper aerodigestive tract, CRC colorectal cancer, NHL non-Hodgkin lymphoma, CUP cancer of unknown primary, RR relative risk, 95%CI 95% confidence interval